229 related articles for article (PubMed ID: 20373594)
1. Niacin, an old drug with new perspectives for the management of dyslipidaemia.
Benhalima K; Muls E
Acta Clin Belg; 2010; 65(1):23-8. PubMed ID: 20373594
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of extended-release niacin with laropiprant.
Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
[TBL] [Abstract][Full Text] [Related]
3. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
Paolini JF; Bays HE; Ballantyne CM; Davidson M; Pasternak R; Maccubbin D; Norquist JM; Lai E; Waters MG; Kuznetsova O; Sisk CM; Mitchel YB
Cardiol Clin; 2008 Nov; 26(4):547-60. PubMed ID: 19031552
[TBL] [Abstract][Full Text] [Related]
4. Extended-release niacin (nicotinic acid)/laropiprant.
Perry CM
Drugs; 2009 Aug; 69(12):1665-79. PubMed ID: 19678716
[TBL] [Abstract][Full Text] [Related]
5. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
[TBL] [Abstract][Full Text] [Related]
6. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
Parhofer KG
Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Shah S; Ceska R; Gil-Extremera B; Paolini JF; Giezek H; Vandormael K; Mao A; McCrary Sisk C; Maccubbin D
Int J Clin Pract; 2010 May; 64(6):727-38. PubMed ID: 20518948
[TBL] [Abstract][Full Text] [Related]
8. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
[TBL] [Abstract][Full Text] [Related]
10. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
McKenney J; Bays H; Koren M; Ballantyne CM; Paolini JF; Mitchel Y; Betteridge A; Kuznetsova O; Sapre A; Sisk CM; Maccubbin D
J Clin Lipidol; 2010; 4(2):105-112.e1. PubMed ID: 21122637
[TBL] [Abstract][Full Text] [Related]
11. The mechanism and mitigation of niacin-induced flushing.
Kamanna VS; Ganji SH; Kashyap ML
Int J Clin Pract; 2009 Sep; 63(9):1369-77. PubMed ID: 19691622
[TBL] [Abstract][Full Text] [Related]
12. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
[TBL] [Abstract][Full Text] [Related]
13. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
[TBL] [Abstract][Full Text] [Related]
14. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
Yiu KH; Cheung BM; Tse HF
Expert Opin Investig Drugs; 2010 Mar; 19(3):437-49. PubMed ID: 20141348
[TBL] [Abstract][Full Text] [Related]
15. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of flushing due to niacin and abolition of these effects.
Sood A; Arora R
J Clin Hypertens (Greenwich); 2009 Nov; 11(11):685-9. PubMed ID: 19878384
[TBL] [Abstract][Full Text] [Related]
17. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients.
Kush D; Hu DY; Ye P; Kim HS; Chen E; Sirah W; McCrary Sisk C; Paolini JF; Maccubbin D
Cardiology; 2009; 114(3):192-8. PubMed ID: 19602880
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
[TBL] [Abstract][Full Text] [Related]
19. A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
Jacobson TA
Mayo Clin Proc; 2010 Apr; 85(4):365-79. PubMed ID: 20360295
[TBL] [Abstract][Full Text] [Related]
20. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation.
Cefali EA; Simmons PD; Stanek EJ; Shamp TR
Int J Clin Pharmacol Ther; 2006 Dec; 44(12):633-40. PubMed ID: 17190373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
